Neurocrine Biosciences (NASDAQ:NBIX) Sets New 1-Year High – Here’s What Happened

Posted by Geri Gentry on Jul 6th, 2026

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $180.00 and last traded at $173.5810, with a volume of 2867 shares traded. The stock had previously closed at $174.26.

Wall Street Analyst Weigh In

A number of analysts recently commented on NBIX shares. The Goldman Sachs Group assumed coverage on Neurocrine Biosciences in a research report on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 target price for the company. Wall Street Zen raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 25th. JPMorgan Chase & Co. boosted their price objective on Neurocrine Biosciences from $177.00 to $185.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Guggenheim restated a “buy” rating and set a $175.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, May 6th. Finally, HC Wainwright upped their target price on Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $187.52.

View Our Latest Report on NBIX

Neurocrine Biosciences Stock Performance

The company has a market cap of $17.28 billion, a price-to-earnings ratio of 26.44, a price-to-earnings-growth ratio of 0.69 and a beta of 0.39. The stock’s fifty day moving average is $155.99 and its two-hundred day moving average is $141.73.

Insider Activity

In other news, Director Stephen A. Sherwin sold 25,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $165.32, for a total value of $4,133,000.00. Following the completion of the sale, the director directly owned 15,860 shares of the company’s stock, valued at $2,621,975.20. This represents a 61.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leslie V. Norwalk sold 1,250 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $168.06, for a total value of $210,075.00. Following the completion of the transaction, the director owned 2,838 shares in the company, valued at $476,954.28. This represents a 30.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 365,234 shares of company stock worth $57,031,540. Company insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Neurocrine Biosciences

Large investors have recently bought and sold shares of the stock. Nilsine Partners LLC purchased a new position in shares of Neurocrine Biosciences in the 4th quarter worth approximately $1,197,000. Ruffer LLP purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $2,479,000. Korea Investment CORP increased its position in shares of Neurocrine Biosciences by 94.3% during the third quarter. Korea Investment CORP now owns 71,689 shares of the company’s stock valued at $10,064,000 after acquiring an additional 34,800 shares during the last quarter. Nordea Investment Management AB lifted its holdings in Neurocrine Biosciences by 81.3% during the fourth quarter. Nordea Investment Management AB now owns 27,202 shares of the company’s stock worth $3,834,000 after acquiring an additional 12,195 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its holdings in Neurocrine Biosciences by 17,250.0% during the third quarter. CIBC Private Wealth Group LLC now owns 7,981 shares of the company’s stock worth $1,120,000 after acquiring an additional 7,935 shares during the period. 92.59% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.